LUKAFER – Calcium Leucovorin Injection 50 mg
Product Overview
LUKAFER (Calcium Leucovorin Injection 50 mg) is a sterile injectable formulation containing Calcium Leucovorin, a reduced folate used in oncology supportive care. It is indicated for methotrexate rescue therapy, helping reduce the toxic effects of high-dose methotrexate on healthy cells. It is also used in combination with 5-Fluorouracil (5-FU) to enhance the effectiveness of chemotherapy in the treatment of advanced colorectal cancer.
LUKAFER should be administered only under the supervision of qualified healthcare professionals in hospital or oncology settings.
| Attribute | Details |
|---|---|
| Brand Name | LUKAFER |
| Generic Name | Calcium Leucovorin Injection |
| Strength | 50 mg |
| Dosage Form | Injection |
| Packaging | 1 × 1 Vial |
| Therapeutic Category | Oncology Supportive Care / Reduced Folate |
| Route of Administration | Intravenous (IV) / Intramuscular (IM) as prescribed |
| Prescription Status | Prescription Medicine |
| Manufacturer | Pharmafer Pvt. Ltd. |
| Storage | Store below 30°C. Protect from light. Do not freeze. |
Uses of LUKAFER
LUKAFER is indicated for:
- Rescue therapy following high-dose methotrexate treatment
- Reduction of methotrexate toxicity
- Combination therapy with 5-Fluorouracil (5-FU) for advanced colorectal cancer
- Treatment of folate deficiency when oral folic acid therapy is not appropriate, as determined by the treating physician
- Oncology supportive care in hospital settings
Benefits
Reduces Methotrexate Toxicity
Helps protect healthy cells from the toxic effects of high-dose methotrexate therapy without reducing its anticancer activity when administered according to established treatment protocols.
Enhances Chemotherapy Effectiveness
When combined with 5-Fluorouracil, Calcium Leucovorin enhances the anticancer activity of treatment in eligible colorectal cancer patients.
Essential Oncology Support
An important component of modern chemotherapy protocols used in hospitals and oncology centers worldwide.
Reliable Injectable Formulation
Sterile injectable formulation suitable for administration by trained healthcare professionals.
Trusted Clinical Therapy
Widely used in oncology practice as part of evidence-based cancer treatment protocols.
Possible Side Effects
Like all medicines, LUKAFER may cause side effects, although not everyone experiences them.
Possible side effects include:
- Nausea
- Vomiting
- Injection site reactions
- Fever
- Allergic or hypersensitivity reactions (rare)
- Sleep disturbances (rare)
Patients should immediately report symptoms such as difficulty breathing, swelling, or severe allergic reactions to their healthcare provider.
Mechanism of Action
Calcium Leucovorin is the active, reduced form of folic acid. It bypasses inhibition of the dihydrofolate reductase enzyme and replenishes reduced folate stores in normal cells. This helps reduce the toxic effects of high-dose methotrexate therapy. When administered with 5-Fluorouracil, it stabilizes the drug’s interaction with its target enzyme, enhancing its anticancer activity.
Dosage & Administration
LUKAFER should be administered only under the supervision of a qualified oncologist or healthcare professional. The dosage, route of administration, and duration of therapy depend on the chemotherapy protocol, the patient’s clinical condition, and the intended indication. It may be administered by intravenous or intramuscular injection according to established oncology guidelines. Patients should receive treatment only in an appropriate clinical setting with regular monitoring.
Frequently Asked Questions
LUKAFER is used as rescue therapy following high-dose methotrexate treatment and in combination with 5-Fluorouracil for the treatment of advanced colorectal cancer.
It replenishes reduced folate in healthy cells, reducing methotrexate toxicity. When combined with 5-Fluorouracil, it enhances the effectiveness of chemotherapy.
LUKAFER should only be administered by qualified healthcare professionals in hospitals or oncology centers.
LUKAFER is primarily used as supportive therapy or in combination with specific chemotherapy medicines as prescribed by an oncologist.
Yes. Patients receiving chemotherapy should be monitored according to the prescribed treatment protocol and clinical response.
